title: Mimotope vaccine efficacy gets a "boost" from native tumor antigens.
abstract: Tumor-associated antigen (TAA)-targeting mimotope peptides exert more prominent immunostimulatory functions than unmodified TAAs, with the caveat that some T-cell clones exhibit a relatively low affinity for TAAs. Combining mimotope-based vaccines with native TAAs in a prime-boost setting significantly improves antitumor immunity.
authors.affiliation: Integrated Department of Immunology; University of Colorado School of Medicine; Denver CO, USA.
authors.forename: Jonathan D
authors.initials: JD
authors.lastname: Buhrman
authors.forename: Jill E
authors.initials: JE
authors.lastname: Slansky
keywords: T cell; cancer immunotherapy; mimotope; peptide vaccine; tumor antigen